Repository logo
 

Protein modification via alkyne hydrosilylation using a substoichiometric amount of ruthenium(II) catalyst

Published version
Peer-reviewed

Type

Article

Change log

Authors

Kwan, TT-L 
Boutureira, O 
Frye, EC 
Walsh, SJ 
Gupta, MK 

Abstract

Transition metal catalysis has emerged as a powerful strategy to expand synthetic flexibility of protein modification. Herein, we report a cationic Ru(II) system that enables the first example of alkyne hydrosilylation between dimethylarylsilanes and O-propargyl-functionalized proteins using a substoichiometric amount or low-loading of Ru(II) catalyst to achieve the first C–Si bond formation on full-length substrates. The reaction proceeds under physiological conditions at a rate comparable to other widely used bioorthogonal reactions. Moreover, the resultant gem-disubstituted vinylsilane linkage can be further elaborated through thiol–ene coupling or fluoride-induced protodesilylation, demonstrating its utility in further rounds of targeted modifications.

Description

Keywords

3402 Inorganic Chemistry, 3405 Organic Chemistry, 34 Chemical Sciences

Journal Title

Chemical Science

Conference Name

Journal ISSN

2041-6520
2041-6539

Volume Title

8

Publisher

Royal Society of Chemistry
Sponsorship
Engineering and Physical Sciences Research Council (EP/J016012/1)
European Research Council (279337)
Royal Society (WM150022)
The Royal Society (uf110046)
European Research Council (676832)
Engineering and Physical Sciences Research Council (EP/M003647/1)
Engineering and Physical Sciences Research Council (EP/P020291/1)
European Commission (EC) (852985)
This work was supported by the EU, EPSRC, BBSRC, MRC, Wellcome Trust and ERC (FP7/2007-2013; 279337/DOS). We thank Dr André Neves and Prof. Kevin Brindle for providing the C2Am protein. T. T.-L. Kwan acknowledges a scholarship from the Cambridge Trusts and the Croucher Foundation of Hong Kong and O. B. thanks the European Commission (Marie Curie IEF) for financial support. S. J. W. acknowledges a scholarship from AstraZeneca and the Cambridge Trusts. S. W. is the recipient of a Career Development Fellowship from the Medical Research Council. G. J. L. B. is a Royal Society University Research Fellow and the recipient of an ERC Staring Grant (TagIt). Work in the Chin lab was supported by the Medical Research Council, UK (MC_U105181009 and MC_UP_A024_1008) to J. W. C.